ImmunoGen Company Profile (NASDAQ:IMGN)

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMGN
  • CUSIP: 45253H10
  • Web: www.immunogen.com
Capitalization:
  • Market Cap: $735.04 million
  • Outstanding Shares: 89,597,000
Average Prices:
  • 50 Day Moving Avg: $6.59
  • 200 Day Moving Avg: $5.25
  • 52 Week Range: $1.51 - $8.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.65
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $83.41 million
  • Price / Sales: 7.20
  • Book Value: ($1.93) per share
  • Price / Book: -3.47
Profitability:
  • EBIDTA: ($69,450,000.00)
  • Net Margins: -117.80%
  • Return on Assets: -52.58%
Debt:
  • Debt-to-Equity Ratio: -0.56%
  • Current Ratio: 2.40%
  • Quick Ratio: 2.34%
Misc:
  • Average Volume: 3.76 million shs.
  • Beta: 2.37
  • Short Ratio: 5.29
 

Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings data on Friday, July, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.07. The firm earned $39.02 million during the quarter, compared to analyst estimates of $30.59 million. The company's quarterly revenue was up 426.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.53) earnings per share. View ImmunoGen's Earnings History.

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?

8 equities research analysts have issued 12-month price targets for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they anticipate ImmunoGen's share price to reach $8.05 in the next twelve months. View Analyst Ratings for ImmunoGen.

What are analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

  • 1. Cantor Fitzgerald analysts commented, "IMGN’s speed to market strategy with mirvetuximab soravtansine is intended to advance the drug through the regulatory process by the end of 2020 (FORWARD I), and it is on track." (9/25/2017)
  • 2. Cowen and Company analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
  • 3. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:

  • Stephen C. McCluski, Independent Chairman of the Board
  • Mark J. Enyedy, President, Chief Executive Officer, Director
  • David B. Johnston PhD, Chief Financial Officer, Executive Vice President
  • Ellie Harrison, Chief Human Resource Officer, Vice President
  • Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
  • John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
  • Craig Barrows, Vice President, General Counsel, Secretary
  • Peter J. Williams, Vice President - Business Development
  • Mark A. Goldberg M.D., Independent Director
  • Dean Jonathan Mitchell, Independent Director

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (6.43%), Redmile Group LLC (5.82%), POLYGON MANAGEMENT LTD. (5.20%), Vanguard Group Inc. (4.87%), State Street Corp (4.62%) and Wells Fargo & Company MN (1.81%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including KBC Group NV, Pinnacle Associates Ltd., Wells Fargo & Company MN, Teachers Advisors LLC, Creative Planning, Swiss National Bank, UBS Asset Management Americas Inc. and Northern Trust Corp. View Insider Buying and Selling for ImmunoGen.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Redmile Group LLC, EAM Investors LLC, Candriam Luxembourg S.C.A., Farallon Capital Management LLC, AXA and Paulson & CO. Inc.. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of ImmunoGen stock can currently be purchased for approximately $6.70.


MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $8.05 (20.15% upside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingHold$5.00LowView Rating Details
8/30/2017Canaccord GenuityReiterated RatingBuy$8.00 -> $10.00MediumView Rating Details
8/29/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
8/29/2017Leerink SwannReiterated RatingOutperform -> BuyHighView Rating Details
8/7/2017Jefferies Group LLCReiterated RatingBuy$9.00MediumView Rating Details
7/6/2017Royal Bank Of CanadaUpgradeSector Perform -> Outperform$5.00 -> $12.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 -> $1.30N/AView Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetHold$9.00 -> $5.00N/AView Rating Details
11/10/2015Oppenheimer Holdings, Inc.Reiterated RatingBuy$24.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for ImmunoGen (NASDAQ:IMGN)
Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)
Earnings History by Quarter for ImmunoGen (NASDAQ IMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2017Q2 2017($0.17)($0.10)$30.59 million$39.02 millionViewN/AView Earnings Details
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
2017 EPS Consensus Estimate: ($1.18)
2018 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20173($0.35)$0.17($0.07)
Q3 20173($0.46)($0.37)($0.41)
Q4 20172($0.40)($0.34)($0.37)
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 67.57%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Craig BarrowsVPSell37,050$6.81$252,310.50View SEC Filing  
9/13/2017Craig BarrowsVPSell14,600$6.95$101,470.00View SEC Filing  
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.00View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.00View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.00View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
Source:
DateHeadline
americanbankingnews.com logoCantor Fitzgerald Reaffirms "Hold" Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - September 25 at 6:38 PM
finance.yahoo.com logoImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : September 25, 2017
finance.yahoo.com - September 25 at 6:24 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Downgraded by ValuEngine
www.americanbankingnews.com - September 23 at 8:32 PM
finance.yahoo.com logoImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22, 2017
finance.yahoo.com - September 22 at 1:57 PM
americanbankingnews.com logoAnalyzing ImmunoGen (IMGN) and Heron Therapeutics (HRTX)
www.americanbankingnews.com - September 22 at 4:34 AM
americanbankingnews.com logo Analysts Expect ImmunoGen, Inc. (IMGN) Will Post Quarterly Sales of $23.69 Million
www.americanbankingnews.com - September 21 at 7:04 AM
finance.yahoo.com logoImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying
finance.yahoo.com - September 19 at 12:18 AM
finance.yahoo.com logoIs ImmunoGen Running Out of Steam, or Taking a Breather?
finance.yahoo.com - September 16 at 7:03 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) VP Sells $101,470.00 in Stock
www.americanbankingnews.com - September 15 at 8:02 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) VP Craig Barrows Sells 37,050 Shares
www.americanbankingnews.com - September 15 at 4:30 PM
fool.com logoWhy Shares of ImmunoGen, Inc. Sank Today
www.fool.com - September 12 at 6:53 PM
seekingalpha.com logoImmunoGen (IMGN) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 12 at 1:39 AM
finance.yahoo.com logoBehind Jazz’s Strategic Collaboration with ImmunoGen
finance.yahoo.com - September 7 at 8:04 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 10:42 PM
finance.yahoo.com logoImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
finance.yahoo.com - September 6 at 6:20 AM
finance.yahoo.com logoImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
finance.yahoo.com - September 1 at 8:14 PM
nasdaq.com logoImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - September 1 at 12:52 AM
americanbankingnews.com logo-$0.30 Earnings Per Share Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - August 31 at 10:30 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc.
finance.yahoo.com - August 31 at 7:49 PM
finance.yahoo.com logoImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue?
finance.yahoo.com - August 31 at 7:49 PM
finance.yahoo.com logoETFs with exposure to ImmunoGen, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 7:49 PM
americanbankingnews.com logoLeerink Swann Analysts Raise Earnings Estimates for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 31 at 9:24 AM
seekingalpha.com logoImmunogen Inks Jazz Deal: Moves To Push Tech To Limits - Seeking Alpha
seekingalpha.com - August 31 at 6:11 AM
fool.com logoWhy Investors Bid Immunogen Inc. Up Almost 12% Today
www.fool.com - August 30 at 6:25 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - August 30 at 11:36 AM
benzinga.com logoImmunoGen Higher After Announcing Strategic Collaboration With Jazz Pharma
www.benzinga.com - August 30 at 2:09 AM
rttnews.com logoACHV Focuses On Achievement, IMGN Strikes Chord With JAZZ, FDA Snubs ACOR
www.rttnews.com - August 30 at 2:09 AM
finance.yahoo.com logoJazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products
finance.yahoo.com - August 30 at 2:09 AM
finance.yahoo.com logoAcorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers
finance.yahoo.com - August 30 at 2:08 AM
finance.yahoo.com logoImmunoGen and Jazz Enter Into Global Collaboration
finance.yahoo.com - August 30 at 2:08 AM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Receives Hold Rating from Cowen and Company
www.americanbankingnews.com - August 29 at 9:28 PM
americanbankingnews.com logoLeerink Swann Reiterates Positive Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 29 at 4:06 PM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - August 26 at 4:22 PM
finance.yahoo.com logoImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 6:13 AM
americanbankingnews.com logoFinancial Contrast: Agenus (AGEN) and ImmunoGen (IMGN)
www.americanbankingnews.com - August 22 at 8:26 PM
finance.yahoo.com logoImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : August 16, 2017
finance.yahoo.com - August 16 at 7:49 PM
finance.yahoo.com logoImmunoGen, Partnerships, Analyst Targets, Pipeline, and Guidance
finance.yahoo.com - August 16 at 1:13 AM
americanbankingnews.com logoZacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $23.69 Million
www.americanbankingnews.com - August 15 at 7:40 AM
americanbankingnews.com logo Brokerages Expect ImmunoGen, Inc. (NASDAQ:IMGN) to Announce -$0.27 EPS
www.americanbankingnews.com - August 13 at 10:28 AM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 12 at 10:50 PM
bizjournals.com logoTechnical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma
www.bizjournals.com - August 11 at 11:08 PM
seekingalpha.com logoImmunoGen (IMGN) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 11:08 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - August 7 at 10:14 AM
finance.yahoo.com logoImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : August 5, 2017
finance.yahoo.com - August 5 at 1:04 AM
americanbankingnews.com logoImmunoGen, Inc. (IMGN) to Post FY2017 Earnings of ($0.84) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - August 3 at 9:52 AM
finance.yahoo.com logoHere's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
finance.yahoo.com - August 2 at 11:22 PM
fool.com logoHere's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
www.fool.com - August 2 at 4:36 PM
finance.yahoo.com logoImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference
finance.yahoo.com - August 1 at 8:26 PM
fool.com logoImmunoGen, Inc. Earnings: What Goes Up, Must Come Down - Motley Fool
www.fool.com - August 1 at 5:15 AM
fool.com logoImmunoGen, Inc. Earnings: What Goes Up, Must Come Down
www.fool.com - July 31 at 4:28 PM

Social

Chart

ImmunoGen (IMGN) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff